118996-64-8

Basic information

• Product Name: 6-methylthio-4-morpholino-2-phenylpyrimidine-5-carbonitrile
• CAS NO: 118996-64-8
• Molecular Weight: 312.395
• Mol File: 118996-64-8.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 6-methylthio-4-morpholino-2-phenylpyrimidine-5-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 6-methylthio-4-morpholino-2-phenylpyrimidine-5-carbonitrile(118996-64-8)
• EPA Substance Registry System: 6-methylthio-4-morpholino-2-phenylpyrimidine-5-carbonitrile(118996-64-8)

Safety Data

• Hazardous Substances Data: 118996-64-8(Hazardous Substances Data)

Upstream product

• 110-91-8 morpholine 
• 118996-61-5 4-chloro-6-methylsulfanyl-2-phenyl-pyrimidine-5-carbonitrile 
• 15908-64-2 3,4-dihydro-6-methymercapto-4-oxo-2-phenylpyrimidine-5-carbonitrile 
• 5147-80-8 [Bis(methylthio)methylene]malononitrile 
• 3490-92-4 methyl 2-cyano-3,3-bis(methylsulfanyl)acrylate 
• 55-21-0 benzamide 
• 1670-14-0 benzamidine monohydrochloride 

Downstream Products

• 118996-78-4 5-amino-4-hydrazino-2-phenyl-7H-pyrazolo<3,4-d>pyrimidine 

Relevant articles and documents

New heterocyclic compounds

Provided herein are heterocyclic compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compositions, metabolites and prodrugs thereof, wherein R1, R2, R3, R4 and R5 are as described herein. Further described herein in particular are heterocyclic compounds of the formula (I) for treating various diseases. and disorders by administering in a patient one or more TNF-α, Thromboxane synthase, 5-LOX, and PDE4 inhibitors. In particular described herein are methods for treating immunological diseases, inflammation, pain disorder, rheumatoid arthritis; osteoporosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; ischemic heart disease; atherosclerosis; cancer; ischemic-induced cell damage; pancreatic beta cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; muscle degeneration; cachexia; asthma; bone resorption diseases; ischemia reperfusion injury; brain trauma; multiple sclerosis; sepsis; septic shock; toxic shock syndrome; fever, and myalgias due to infection and diseases mediated by HIV-1; HIV-2; HIV-3; cytomegalovirus (CMV); influenza; adenovirus; the herpes viruses (including HSV-1, HSV-2) and herpes zoster viruses in a mammal comprising administering an effective amount of a compound of formula (I).